Drug Trial Radar · NCT06770881
JSKN033 in Chinese Subjects with Advanced Malignant Tumors
Last checked: Nov 19, 2026Latest source record: Jan 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
430
Planned (sponsor's estimate)
Start
Jan 15, 2025
Primary completion
Dec 31, 2026
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I/II multicenter study to evaluate the safety and efficacy of JSKN033 in Chinese subjects with unresectable locally advanced/metastatic solid tumors.
Conditions
- Advanced Malignant Tumors
Interventions
JSKN033Drug
JSKN033 should be administered subcutaneously on the first day of each week cycle/ each 2-week cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity (DLT)Time frame: Up to 12 months
- Maximum Tolerated Dose (MTD) or recommend Phase II dose (RP2D).Time frame: Up to 12 months
- Percentage of Participants Experiencing Any Treatment Emergent Adverse Events (TEAE) and Treatment Related Adverse Events (TRAE)Time frame: Throughout the duration of the study, approximately 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.